Vertex Pharmaceuticals Incorporated
- Country
- ๐บ๐ธUnited States
- Ownership
- Public
- Established
- 1989-01-01
- Employees
- 5.4K
- Market Cap
- $123.9B
- Website
- http://www.vrtx.com
A Safety and Efficacy Study Evaluating CTX001 in Subjects With Severe Sickle Cell Disease
- Conditions
- Interventions
- First Posted Date
- 2018-11-19
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 63
- Registration Number
- NCT03745287
- Locations
- ๐บ๐ธ
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
๐บ๐ธSt. Jude Children's Research Hospital, Memphis, Tennessee, United States
๐บ๐ธUniversity of Illinois at Chicago Hospitals and Health Systems, Chicago, Illinois, United States
Evaluation of VX 445/TEZ/IVA in Cystic Fibrosis Subjects 6 Through 11 Years of Age
- First Posted Date
- 2018-10-02
- Last Posted Date
- 2021-10-22
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 71
- Registration Number
- NCT03691779
- Locations
- ๐บ๐ธ
Ann & Robert Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
๐บ๐ธChildren's Hospital of Orange County, Orange, California, United States
๐ฆ๐บThe Children's Hospital at Westmead, Westmead, Australia
A Safety and Efficacy Study Evaluating CTX001 in Subjects With Transfusion-Dependent ฮฒ-Thalassemia
- Conditions
- Interventions
- First Posted Date
- 2018-08-31
- Last Posted Date
- 2024-09-30
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 59
- Registration Number
- NCT03655678
- Locations
- ๐บ๐ธ
Lucile Packard Children's Hospital, Palo Alto, California, United States
๐บ๐ธColumbia University Medical Center (21+ years), New York, New York, United States
๐บ๐ธColumbia University Medical Center, New York, New York, United States
Evaluation of VX-659/TEZ/IVA in Cystic Fibrosis Subjects 6 Through 11 Years of Age
- First Posted Date
- 2018-08-16
- Last Posted Date
- 2020-02-05
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 18
- Registration Number
- NCT03633526
- Locations
- ๐บ๐ธ
Children's Hospital Colorado, Aurora, Colorado, United States
๐บ๐ธAnn & Robert Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
๐บ๐ธClinical Research of Charlotte, Charlotte, North Carolina, United States
A Study to Explore the Impact of Lumacaftor/Ivacaftor on Disease Progression in Subjects Aged 2 Through 5 Years With Cystic Fibrosis, Homozygous for F508del
- First Posted Date
- 2018-08-10
- Last Posted Date
- 2022-11-02
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 51
- Registration Number
- NCT03625466
- Locations
- ๐ฉ๐ช
Heidelberg Cystic Fibrosis Center, Heidelberg, Germany
๐ฉ๐ชHannover Medical School, Hannover, Germany
๐ฉ๐ชUniversitatsklinikum Schleswig-Holstein, Klinik fรผr Kinder- und Jugendmedizin, Lubeck, Germany
Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Participants 1 to Less Than 2 Years of Age With Cystic Fibrosis, Homozygous for F508del
- First Posted Date
- 2018-07-26
- Last Posted Date
- 2023-01-06
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 61
- Registration Number
- NCT03601637
- Locations
- ๐บ๐ธ
Children's Medical Center of Dallas, Dallas, Texas, United States
๐บ๐ธChildren's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
๐บ๐ธSeattle Children's Hospital, Seattle, Washington, United States
A Study to Evaluate Efficacy and Safety of TEZ/IVA in Subjects Aged 6 Through 11 Years With Cystic Fibrosis
- First Posted Date
- 2018-06-15
- Last Posted Date
- 2020-02-11
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 67
- Registration Number
- NCT03559062
- Locations
- ๐ฉ๐ช
Universitaetsklinikum Koeln, Koeln, Germany
๐ซ๐ทGroupe Hospitalier Pellegrin - Hรดpital des Enfants, Bordeaux Cedex, France
๐ฆ๐บLady Cilento Children's Hospital, South Brisbane, Australia
A Study to Evaluate the Safety and Efficacy of Long-term Treatment With TEZ/IVA in CF Participants With an F508del CFTR Mutation
- First Posted Date
- 2018-05-25
- Last Posted Date
- 2024-04-19
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 130
- Registration Number
- NCT03537651
- Locations
- ๐บ๐ธ
St. Luke's CF Center of Idaho, Boise, Idaho, United States
๐บ๐ธBoston Children's Hospital, Boston, Massachusetts, United States
๐บ๐ธSUNY Upstate Medical University, Syracuse, New York, United States
A Study of VX-445 Combination Therapy in CF Subjects Homozygous for F508del (F/F)
- Conditions
- Interventions
- First Posted Date
- 2018-05-15
- Last Posted Date
- 2020-01-27
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 113
- Registration Number
- NCT03525548
- Locations
- ๐ง๐ช
Universitair Ziekenhuis Brussel - Campus Jette, Brussels, Belgium
๐ง๐ชUZ Antwerpen, Edegem, Belgium
๐ง๐ชUniversitair Ziekenhuis Gent, Gent, Belgium
A Phase 3 Study of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)
- First Posted Date
- 2018-05-15
- Last Posted Date
- 2020-05-19
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 405
- Registration Number
- NCT03525444
- Locations
- ๐บ๐ธ
Maine Medical Partners, Portland, Maine, United States
๐บ๐ธUniversity of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
๐บ๐ธMiller Children's Hospital/ Long Beach Memorial, Long Beach, California, United States